This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): Long-acting Risperdal (risperidone) Injection, RLAI
Description: Risperdal Consta is a long-acting, injectable form of Risperdal that uses extended release microspheres. Risperdal Consta uses Alkermes' proprietary Medisorb technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Alkermes is the exclusive manufacturer of Risperdal Consta and receives both manufacturing fees and royalties from Janssen. Under the manufacturing and supply agreement, Alkermes records manufacturing revenues based on a percentage of Janssen's net selling price. These percentages are based on the volume of units shipped to Janssen in any given calendar year, with a minimum manufacturing fee of 7.5%.
In fiscal 2005, Alkermes manufacturing revenue was based on an average of 8.1% of Janssen's net sales price for Risperdal Consta compared to 9.8% in fiscal 2004 and 12.3% in fiscal 2003. Under the license agreements with Janssen, Alkermes also records royalty revenues equal to 2.5% of Janssen's net sales of Risperdal Consta.
Partners: Alkermes plc
Risperdal Consta News
Pink Sheet J&J Risperdal Consta “non-approvable”
Additional information available to subscribers only: